Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?

Drug Metabolism and Disposition

Volumn 29, Issue 11, 2001, Pages 1514-1520

  Yu, Aiming ^a   Haining, Robert L ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DRUG METABOLITE; KETOCONAZOLE; N DEMETHYLASE; NORLEVORPHANOL; QUINIDINE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DEXTRORPHAN; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0034782996     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
2. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline
3. The urinary excretion of dextromethorphan and three metabolites in dogs and humans
4. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
5. Effects of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver
6. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
7. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine and its metabolites
8. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 DB1 activity
9. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
10. i values and impact of CYP3A5 expression
11. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A(CYP3A) subfamily
12. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivities of the wild-type and 1359L mutant forms
13. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans
14. Quantification of dextromethorphan and metabolites: A dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity
15. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation
16. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity
17. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes
18. Identification of cytochrome P450 isoforms involved in citalopram Ndemethylation by human liver microsomes
19. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan and verapamil
20. Pharmacogenetics of dextromethorphan Odemethylation in man
21. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s
22. The genetic polymorphism of debrisoquine/ sparteine metabolism - Molecular mechanisms
23. Azelastine N-demethylation by cytochrome P450 (CYP)3A4. CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs
24. Inter-individual variation in the metabolism of dextromethorphan
25. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C5
26. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
27. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
28. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
29. Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1
30. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
31. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
32. Inhibition of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
33. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
34. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole
35. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
36. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes
37. Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine
38. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone
39. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
40. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6